Vitrafy Life Sciences Ltd. (VFY.AX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in AUDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | AUD m | - | - | - | - | - | - | - | - |
| Operating profit | AUD m | - | |||||||
| Net profit | AUD m | - | - | - | - | - | - | - | - |
| EPS reported | AUD | - | |||||||
| Operating cashflow per share | AUD | - | |||||||
| Capex per share | AUD | - | |||||||
| FCF per share | AUD | - | |||||||
| Free cash flow | AUD m | - | |||||||
| Net debt | AUD m | - | |||||||
| Book value equity | AUD m | - | |||||||
| Book value per share | AUD | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | AUD | - |
Financial summary
Financials in AUDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Vitrafy Life Sciences Limited has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets, cell & gene therapies, aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems. Vitrafy has designed and developed an innovative cryopreservation solution, which includes smart cryopreservation medical devices and packaging, and a sample quality management software platform known as LifeChain.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Vitrafy Life Sciences Limited has developed cryopreservation technology that dramatically improves cell survival rates across multiple applications including blood platelets, cell & gene therapies, aquaculture and bovine reproduction. The Company provides complete cryopreservation solutions through its managed service revenue model, utilising its FDA-registered Smart Freezing and Smart Thawing devices, integrated LifeChain software platform, and Smart Packaging systems. Vitrafy has designed and developed an innovative cryopreservation solution, which includes smart cryopreservation medical devices and packaging, and a sample quality management software platform known as LifeChain.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free